VAREX IMAGING CORP (VREX) Fundamental Analysis & Valuation

NASDAQ:VREXUS92214X1063

Current stock price

12.01 USD
+0.41 (+3.53%)
At close:
12.01 USD
0 (0%)
After Hours:

This VREX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. VREX Profitability Analysis

1.1 Basic Checks

  • In the past year VREX was profitable.
  • In the past year VREX had a positive cash flow from operations.
  • In multiple years VREX reported negative net income over the last 5 years.
  • In the past 5 years VREX always reported a positive cash flow from operatings.
VREX Yearly Net Income VS EBIT VS OCF VS FCFVREX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

1.2 Ratios

  • The Return On Assets of VREX (-6.17%) is better than 67.55% of its industry peers.
  • The Return On Equity of VREX (-14.20%) is better than 64.36% of its industry peers.
  • VREX has a better Return On Invested Capital (5.94%) than 78.72% of its industry peers.
  • VREX had an Average Return On Invested Capital over the past 3 years of 4.82%. This is below the industry average of 9.15%.
  • The 3 year average ROIC (4.82%) for VREX is below the current ROIC(5.94%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -6.17%
ROE -14.2%
ROIC 5.94%
ROA(3y)-2.14%
ROA(5y)-0.47%
ROE(3y)-5.1%
ROE(5y)-1.2%
ROIC(3y)4.82%
ROIC(5y)5.54%
VREX Yearly ROA, ROE, ROICVREX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • The Operating Margin of VREX (8.23%) is better than 75.53% of its industry peers.
  • VREX's Operating Margin has declined in the last couple of years.
  • The Gross Margin of VREX (34.15%) is worse than 72.87% of its industry peers.
  • VREX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 8.23%
PM (TTM) N/A
GM 34.15%
OM growth 3Y-8.19%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y5.76%
VREX Yearly Profit, Operating, Gross MarginsVREX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

3

2. VREX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VREX is destroying value.
  • Compared to 1 year ago, VREX has more shares outstanding
  • VREX has more shares outstanding than it did 5 years ago.
  • VREX has a better debt/assets ratio than last year.
VREX Yearly Shares OutstandingVREX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
VREX Yearly Total Debt VS Total AssetsVREX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 1.99 indicates that VREX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • VREX has a Altman-Z score (1.99) which is in line with its industry peers.
  • VREX has a Debt/Equity ratio of 0.78. This is a neutral value indicating VREX is somewhat dependend on debt financing.
  • The Debt to Equity ratio of VREX (0.78) is worse than 72.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z 1.99
ROIC/WACC0.78
WACC7.6%
VREX Yearly LT Debt VS Equity VS FCFVREX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • VREX has a Current Ratio of 3.89. This indicates that VREX is financially healthy and has no problem in meeting its short term obligations.
  • VREX has a better Current ratio (3.89) than 62.23% of its industry peers.
  • VREX has a Quick Ratio of 1.87. This is a normal value and indicates that VREX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of VREX (1.87) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.89
Quick Ratio 1.87
VREX Yearly Current Assets VS Current LiabilitesVREX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

6

3. VREX Growth Analysis

3.1 Past

  • VREX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.57%, which is quite impressive.
  • VREX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 57.78% yearly.
  • The Revenue has been growing slightly by 4.09% in the past year.
  • The Revenue has been growing slightly by 2.73% on average over the past years.
EPS 1Y (TTM)78.57%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%171.43%
Revenue 1Y (TTM)4.09%
Revenue growth 3Y-0.58%
Revenue growth 5Y2.73%
Sales Q2Q%4.9%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.31% on average over the next years. This is quite good.
  • VREX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.15% yearly.
EPS Next Y5.25%
EPS Next 2Y10.44%
EPS Next 3Y14.64%
EPS Next 5Y18.31%
Revenue Next Year4.48%
Revenue Next 2Y4.18%
Revenue Next 3Y4.62%
Revenue Next 5Y5.15%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VREX Yearly Revenue VS EstimatesVREX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
VREX Yearly EPS VS EstimatesVREX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

5

4. VREX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 12.01, which indicates a correct valuation of VREX.
  • VREX's Price/Earnings ratio is rather cheap when compared to the industry. VREX is cheaper than 90.96% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of VREX to the average of the S&P500 Index (27.87), we can say VREX is valued rather cheaply.
  • VREX is valuated reasonably with a Price/Forward Earnings ratio of 11.19.
  • VREX's Price/Forward Earnings ratio is rather cheap when compared to the industry. VREX is cheaper than 93.62% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 38.51, VREX is valued rather cheaply.
Industry RankSector Rank
PE 12.01
Fwd PE 11.19
VREX Price Earnings VS Forward Price EarningsVREX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, VREX is valued cheaper than 94.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.66
VREX Per share dataVREX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as VREX's earnings are expected to grow with 14.64% in the coming years.
PEG (NY)2.29
PEG (5Y)0.21
EPS Next 2Y10.44%
EPS Next 3Y14.64%

0

5. VREX Dividend Analysis

5.1 Amount

  • No dividends for VREX!.
Industry RankSector Rank
Dividend Yield 0%

VREX Fundamentals: All Metrics, Ratios and Statistics

VAREX IMAGING CORP

NASDAQ:VREX (4/17/2026, 8:00:02 PM)

After market: 12.01 0 (0%)

12.01

+0.41 (+3.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-05
Inst Owners98.65%
Inst Owner Change0.04%
Ins Owners1.66%
Ins Owner Change14.9%
Market Cap503.22M
Revenue(TTM)854.40M
Net Income(TTM)-67.70M
Analysts83.64
Price Target19.18 (59.7%)
Short Float %3.3%
Short Ratio4.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)69.41%
Min EPS beat(2)40.06%
Max EPS beat(2)98.76%
EPS beat(4)4
Avg EPS beat(4)156.06%
Min EPS beat(4)40.06%
Max EPS beat(4)404.2%
EPS beat(8)6
Avg EPS beat(8)96.39%
EPS beat(12)9
Avg EPS beat(12)67.16%
EPS beat(16)13
Avg EPS beat(16)58.24%
Revenue beat(2)1
Avg Revenue beat(2)0.64%
Min Revenue beat(2)-1.06%
Max Revenue beat(2)2.35%
Revenue beat(4)3
Avg Revenue beat(4)1.84%
Min Revenue beat(4)-1.06%
Max Revenue beat(4)4.57%
Revenue beat(8)4
Avg Revenue beat(8)0.23%
Revenue beat(12)5
Avg Revenue beat(12)0.05%
Revenue beat(16)8
Avg Revenue beat(16)0.29%
PT rev (1m)0%
PT rev (3m)9.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.88%
EPS NY rev (1m)1.4%
EPS NY rev (3m)5.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.54%
Valuation
Industry RankSector Rank
PE 12.01
Fwd PE 11.19
P/S 0.59
P/FCF N/A
P/OCF 31.26
P/B 1.06
P/tB 1.91
EV/EBITDA 7.66
EPS(TTM)1
EY8.33%
EPS(NY)1.07
Fwd EY8.94%
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)0.38
OCFY3.2%
SpS20.39
BVpS11.38
TBVpS6.3
PEG (NY)2.29
PEG (5Y)0.21
Graham Number16.0029 (33.25%)
Profitability
Industry RankSector Rank
ROA -6.17%
ROE -14.2%
ROCE 7.52%
ROIC 5.94%
ROICexc 6.86%
ROICexgc 9.31%
OM 8.23%
PM (TTM) N/A
GM 34.15%
FCFM N/A
ROA(3y)-2.14%
ROA(5y)-0.47%
ROE(3y)-5.1%
ROE(5y)-1.2%
ROIC(3y)4.82%
ROIC(5y)5.54%
ROICexc(3y)5.86%
ROICexc(5y)6.54%
ROICexgc(3y)8.71%
ROICexgc(5y)10.09%
ROCE(3y)6.1%
ROCE(5y)7.01%
ROICexgc growth 3Y-6.75%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.38%
ROICexc growth 5YN/A
OM growth 3Y-8.19%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y5.76%
F-Score5
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA 3.82
Cap/Depr 109.29%
Cap/Sales 3.44%
Interest Coverage 2.18
Cash Conversion 16.56%
Profit Quality N/A
Current Ratio 3.89
Quick Ratio 1.87
Altman-Z 1.99
F-Score5
WACC7.6%
ROIC/WACC0.78
Cap/Depr(3y)77.68%
Cap/Depr(5y)67.38%
Cap/Sales(3y)2.78%
Cap/Sales(5y)2.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.57%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%171.43%
EPS Next Y5.25%
EPS Next 2Y10.44%
EPS Next 3Y14.64%
EPS Next 5Y18.31%
Revenue 1Y (TTM)4.09%
Revenue growth 3Y-0.58%
Revenue growth 5Y2.73%
Sales Q2Q%4.9%
Revenue Next Year4.48%
Revenue Next 2Y4.18%
Revenue Next 3Y4.62%
Revenue Next 5Y5.15%
EBIT growth 1Y79.34%
EBIT growth 3Y-8.72%
EBIT growth 5YN/A
EBIT Next Year53.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-113.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.85%
OCF growth 3Y35.13%
OCF growth 5Y25.87%

VAREX IMAGING CORP / VREX Fundamental Analysis FAQ

What is the fundamental rating for VREX stock?

ChartMill assigns a fundamental rating of 4 / 10 to VREX.


What is the valuation status of VAREX IMAGING CORP (VREX) stock?

ChartMill assigns a valuation rating of 5 / 10 to VAREX IMAGING CORP (VREX). This can be considered as Fairly Valued.


How profitable is VAREX IMAGING CORP (VREX) stock?

VAREX IMAGING CORP (VREX) has a profitability rating of 5 / 10.


What are the PE and PB ratios of VAREX IMAGING CORP (VREX) stock?

The Price/Earnings (PE) ratio for VAREX IMAGING CORP (VREX) is 12.01 and the Price/Book (PB) ratio is 1.06.


What is the expected EPS growth for VAREX IMAGING CORP (VREX) stock?

The Earnings per Share (EPS) of VAREX IMAGING CORP (VREX) is expected to grow by 5.25% in the next year.